Luminex and BD Sign Agreement to Create Diagnostic Tests for Cancer

Luminex Corporation (NASDAQ: LMNX), a worldwide leader in multiplexed solutions, and global medical technology company BD (NYSE: BDX), through its BD Diagnostics-TriPath platform, today announced the signing of a development and supply agreement. Under the terms of the agreement, BD Diagnostics-TriPath will develop, market and sell new biomarker-based diagnostic tests for certain cancers using Luminex’s multiplexing xMAP(R) Technology platform.

Source: Luminex